메뉴 건너뛰기
Expert Opinion on Pharmacotherapy
Volumn 16, Issue 7, 2015, Pages 1117-1118
Current lipid-modifying agents
Author keywords

[No Author keywords available]
Indexed keywords

ANTILIPEMIC AGENT; COLESEVELAM; EZETIMIBE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;
EID: 84928528069     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1035013     Document Type: Letter
Times cited : (5)
References (9)
  • 2
  • 3
    • 84887902711 scopus 로고    scopus 로고
    • Comment on: Clinical benefits of ezetimibe: Absence of proof is just that
    • Doggrell SA. Comment on: Clinical benefits of ezetimibe: absence of proof is just that. Expert Opin Pharmacother 2013;14:2611-2
    • (2013) Expert Opin Pharmacother , vol.14 , pp. 2611-2612
    • Doggrell, S.A.1
  • 5
    • 79959746706 scopus 로고    scopus 로고
    • The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial
    • Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92
    • (2011) Lancet , vol.377 , pp. 2181-2192
    • Baigent, C.1    Landray, M.J.2    Reith, C.3
  • 6
    • 84924628161 scopus 로고    scopus 로고
    • Report of the american heart association (aha) scientific sessions 2014, chicago
    • Kohno T. Report of the American Heart Association (AHA) Scientific Sessions 2014, Chicago. Circ J 2014;79(1):34-40
    • (2014) Circ J , vol.79 , Issue.1 , pp. 34-40
    • Kohno, T.1
  • 7
    • 84915819121 scopus 로고    scopus 로고
    • Inactivating mutations in NPC1L1 and protection from coronary heart disease
    • Stitziel NO, Won HH, Morrison AC, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014;371:2072-82
    • (2014) N Engl J Med , vol.371 , pp. 2072-2082
    • Stitziel, N.O.1    Won, H.H.2    Morrison, A.C.3
  • 8
    • 84861585543 scopus 로고    scopus 로고
    • Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
    • Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314-24
    • (2012) Prog Lipid Res , vol.51 , pp. 314-324
    • Otocka-Kmiecik, A.1    Mikhailidis, D.P.2    Nicholls, S.J.3
  • 9
    • 80051725784 scopus 로고    scopus 로고
    • European panel on low density lipoprotein (LDL) subclasses a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses
    • Mikhailidis DP, Elisaf M, Rizzo M, et al. 'European panel on low density lipoprotein (LDL) subclasses': a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011;9:533-71
    • (2011) Curr Vasc Pharmacol , vol.9 , pp. 533-571
    • Mikhailidis, D.P.1    Elisaf, M.2    Rizzo, M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.